Drug Pipeline

Daratumumab Injection Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
1
Recruiting
1
Phase 3
3
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-03 NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Relapsed or Refractory Multiple Myeloma Not Yet Recruiting
Phase 2
NCT04151667 Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple… Multiple Myeloma Active, Not Recruiting
Phase 1
NCT07260708 Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced… Advanced Cancers Recruiting
Sponsors Running Daratumumab Injection Trials
H. Lee Moffitt Cancer Center and Research Institute (1) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (1) Innovent Biologics (Suzhou) Co. Ltd. (1)
Disease Areas
Multiple Myeloma (2)
Get alerts when Daratumumab Injection trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free